Birchbrook’s TherapeuticsMD TXMD Stock Holding History

Birchbrook’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10	Closed	-$23	–	283
2024 Q1	$23	Hold	10	–	–	﹤0.01%	277
2023 Q4	$23	Buy	+10	New	+$24	﹤0.01%	306

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Birchbrook's TXMD Position: Q2 2024 in Review

Birchbrook sold out of TherapeuticsMD (TXMD) in Q2 2024, closing a stake of 10 shares — an estimated $23 sold.

Birchbrook first reported a position in TXMD in Q4 2023 and held it in 2 quarters. The position peaked at $23 in Q1 2024. 38 funds tracked by Wall St. Rank hold TXMD as of Q2 2024.

Birchbrook reported no remaining TherapeuticsMD position as of Q2 2024 after selling out during the quarter.
Birchbrook sold 10 TherapeuticsMD shares in Q2 2024, an estimated $23.
Birchbrook first reported a position in TherapeuticsMD in Q4 2023 and held it in 2 quarters.
Birchbrook's TherapeuticsMD position peaked at $23 in Q1 2024.
38 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2024.

Based on Birchbrook's 13F filing for Q2 2024, filed 10 Jun 2025.